What does primrose mrna — financial royalty assets, net mean?

Represents the current book value of royalty assets within the mRNA segment after accounting for all impairments and valuation allowances. This figure provides the most accurate reflection of the expected future economic benefits to be derived from these specific royalty rights. It is used by investors to determine the net asset value of the company's intellectual property portfolio.

Ligand Pharmaceuticals LGND Primrose mRNA — Financial Royalty Assets, Net

Other product segments

Qarziba

$103.24M—

Similar metrics at other companies

RPRXIncome from financial royalty assets — Total income and other revenues

$594.99M+10.3%

RGLDRoyalty interest — Stream and royalty interests, net (Note 3)

$4.06B—

BBIODeferred royalty obligations, net

$871.19M+75.2%

TPLRoyalty interests acquired, net

$831.45M+94.0%

RGLDMineral Properties Net

$8.54B+179%

BCPCRoyalty Revenue — Net Sales

$493K+7.6%

Other financials

Income statement

See full

Revenue$51.7M+14.1%

Operating income$17.4M+148%

Net income-$13.3M+68.6%

EPS (diluted)-$0.67+69.7%

Balance sheet

See full

Cash & equivalents$115.1M+140%

Total debt$5.1M+14.2%

Total equity$997.3M+25.4%

Total assets$1.5B+69.2%

Cash flow

See full

Operating cash flow$48.7M+291%

CapEx$228.0K+6.5%

Free cash flow$48.5M+289%

Valuation

See full

Market cap$5.51B+96.7%

Enterprise value$5.4B+95.4%

P/E35.9×—

P/S20.1×+4.6×

Profitability

See full

Gross margin91.9%—

Operating margin34.5%+23.0pp

Net margin55.9%+35.7pp

FCF margin44.8%+16.8pp

Returns & leverage

See full

Return on equity17.1%+11.5pp

Debt / equity0×0.0×

Current ratio21.3×+16.0×

Where this comes from

Reported directly by Ligand Pharmaceuticals in its filing.

Tagged under the XBRL concept lgnd:FinancialRoyaltyAssetsNet.

The official record: Ligand Pharmaceuticals’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about Ligand Pharmaceuticals's primrose mrna — financial royalty assets, net.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Ligand Pharmaceuticals's primrose mrna — financial royalty assets, net?: Ligand Pharmaceuticals (LGND) reported primrose mrna — financial royalty assets, net of $3.18M in Q1 2026.
What does primrose mrna — financial royalty assets, net mean?: Represents the current book value of royalty assets within the mRNA segment after accounting for all impairments and valuation allowances. This figure provides the most accurate reflection of the expected future economic benefits to be derived from these specific royalty rights. It is used by investors to determine the net asset value of the company's intellectual property portfolio.